Resalis Therapeutics secured a strategic equity investment from Sanofi to accelerate the development of its lead candidate, RES-010, through a Phase 2 clinical trial.
Resalis Therapeutics secured a strategic equity investment from Sanofi to accelerate the development of its lead candidate, RES-010, through a Phase 2 clinical trial.
10/28/24, 10:01 AM
Location
turinIndustry
biotechnology
Investors
Sanofi
Resalis Therapeutics announced a strategic equity investment from Sanofi to fast-track the development of RES-010, aimed at obesity treatment. This investment validates their approach and supports advancements towards clinical trials offering potential transformative treatments for obesity.
Company Info
Location
turin, piedmont, italy
Additional Info
Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.